Why the study?
Does dapagliflozin reduce systolic blood pressure and HbA1c in patients with inadequately controlled T2DM and hypertension on renin-angiotensin system blockade?
Population
613 patients with inadequately controlled type 2 diabetes mellitus and hypertension, despite ongoing therapy…
Comparison
Dapagliflozin 10 mg once daily for 12 weeks. vs Placebo once daily for 12 weeks.
Design
RCT, randomized, double-blind
Follow-up
12 weeks
Authors
Loading...
Dapagliflozin offers dual BP and glycemic benefit atop RAS blockade in T2DM; extends SGLT2 inhibitor evidence to hypertensive patients.
Does dapagliflozin reduce systolic blood pressure and HbA1c in patients with inadequately controlled T2DM and hypertension on renin-angiotensin system blockade?
Dapagliflozin provides additional blood pressure and glycemic lowering benefits in patients with T2DM and hypertension already treated with RAS blockers.
Weber et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: